Grant Number:	5R01CA160744-04 Interpret this number
Primary Investigator:	Kim, Jane
Organization:	Harvard School Of Public Health
Project Title:	Comparative and Cost-Effectiveness of Preventing HPV-Related Diseases
Fiscal Year:	2015

DESCRIPTION (provided by applicant): Each year, more than 25,000 cases of invasive cancer attributable to human papillomavirus (HPV) infection occur in the United States; nearly 50% are cervical cancer, while the rest involve the oral cavity/oropharynx, anus, vulva, penis, and vagina. Collectively, these account for substantial morbidity and mortality, contribute to health disparities, and are associated with high economic costs. Advancements in HPV-related cancer epidemiology, coupled with new (e.g., HPV-16,-18 vaccines, HPV DNA testing) and emerging (e.g., biomarkers, therapeutic vaccines) technologies provide a remarkable opportunity to improve cancer prevention efforts. However, critical challenges remain with respect to clinical decision-making and prevention policy, pertaining to knowledge gaps and heterogeneities in the natural history of different cancers, uncertainties in HPV type distribution following HPV-16,-18 vaccination, and the real-world clinical effectiveness of emerging technologies. We propose to employ a decision-analytic approach, developing a flexible modeling framework that will allow us to synthesize the best available data; evaluate the health and economic consequences of alternative strategies; explore the uncertainty around their outcomes; explicitly quantify the tradeoffs associated with different approaches; and inform timely clinical and policy questions. By achieving our aims, we expect to have an impact on (1) the analytic methods of decision science; (2) the equitable distribution and rationale use of new technology; (3) the effectiveness of strategies for cancer prevention through clinical guidelines and national policies; (4) HPV-related cancer outcomes, including reduced incidence, enhanced quality of life, improved survival, and reduced disparities; and (5) the financial and economic profile of delivering cancer-related health services.




Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men.
Authors: Burger E.A. , Dyer M.A. , Sy S. , Palefsky J.M. , de Pokomandy A. , Coutlee F. , Silverberg M.J. , Kim J.J. .
Source: Journal of acquired immune deficiency syndromes (1999), 2018-09-01; 79(1), p. 10-19.
PMID: 29757775
Related Citations

Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Authors: Pedersen K. , Burger E.A. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: European journal of cancer (Oxford, England : 1990), 2018 03; 91, p. 68-75.
EPub date: 2018-01-12.
PMID: 29335156
Related Citations

Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer.
Authors: Burger E.A. , Kim J.J. , Sy S. , Castle P.E. .
Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017-09-15; 65(6), p. 893-899.
PMID: 28531261
Related Citations

Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
Authors: Burger E.A. , Pedersen K. , Sy S. , Kristiansen I.S. , Kim J.J. .
Source: British journal of cancer, 2017-09-05; 117(6), p. 783-790.
EPub date: 2017-08-03.
PMID: 28772279
Related Citations

Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Authors: Kim J.J. , Burger E.A. , Sy S. , Campos N.G. .
Source: Journal of the National Cancer Institute, 2017 02; 109(2), .
EPub date: 2016-10-18.
PMID: 27754955
Related Citations

The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance.
Authors: Burger E.A. , Sy S. , Nygård M. , Kim J.J. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017 01; 26(1), p. 95-103.
EPub date: 2016-09-13.
PMID: 27624639
Related Citations

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Authors: Brisson M. , Bénard É. , Drolet M. , Bogaards J.A. , Baussano I. , Vänskä S. , Jit M. , Boily M.C. , Smith M.A. , Berkhof J. , et al. .
Source: The Lancet. Public health, 2016 11; 1(1), p. e8-e17.
EPub date: 2016-09-27.
PMID: 29253379
Related Citations

Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
Authors: Pedersen K. , Burger E.A. , Sy S. , Kristiansen I.S. , Kim J.J. .
Source: Gynecologic oncology, 2016 Nov; 143(2), p. 326-333.
EPub date: 2016-08-17.
PMID: 27542966
Related Citations

Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.
Authors: Burger E.A. , Lee K. , Saraiya M. , Thompson T.D. , Chesson H.W. , Markowitz L.E. , Kim J.J. .
Source: Cancer, 2016-07-01; 122(13), p. 2057-66.
EPub date: 2016-04-28.
PMID: 27124396
Related Citations

Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Authors: Campos N.G. , Castle P.E. , Wright T.C. , Kim J.J. .
Source: International journal of cancer, 2015-11-01; 137(9), p. 2208-19.
EPub date: 2015-05-21.
PMID: 25943074
Related Citations

Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.
Authors: Burger E.A. , Sy S. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: The Journal of infectious diseases, 2015-01-15; 211(2), p. 206-15.
EPub date: 2014-07-23.
PMID: 25057044
Related Citations

The value of improving failures within a cervical cancer screening program: an example from Norway.
Authors: Burger E.A. , Kim J.J. .
Source: International journal of cancer, 2014-10-15; 135(8), p. 1931-9.
EPub date: 2014-03-20.
PMID: 24615416
Related Citations

Practice-based evidence for primary HPV testing in the United States.
Authors: Kim J.J. .
Source: Journal of the National Cancer Institute, 2014 Aug; 106(8), .
EPub date: 2014-07-18.
PMID: 25038468
Related Citations

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Authors: Burger E.A. , Sy S. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: PloS one, 2014; 9(3), p. e89974.
EPub date: 2014-03-20.
PMID: 24651645
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-31; 31 Suppl 7, p. H1-31.
PMID: 24332295
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-30; 31 Suppl 6, p. G1-31.
PMID: 24331817
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-29; 31 Suppl 5, p. F1-31.
PMID: 24331745
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-11-22; 31 Suppl 8, p. I1-31.
PMID: 24229716
Related Citations

Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high-risk patients.
Authors: Assoumou S.A. , Mayer K.H. , Panther L. , Linas B.P. , Kim J. .
Source: Sexually transmitted diseases, 2013 Apr; 40(4), p. 298-303.
PMID: 23486494
Related Citations

Modeling preventative strategies against human papillomavirus-related disease in developed countries.
Authors: Canfell K. , Chesson H. , Kulasingam S.L. , Berkhof J. , Diaz M. , Kim J.J. .
Source: Vaccine, 2012-11-20; 30 Suppl 5, p. F157-67.
PMID: 23199959
Related Citations